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ABSTRACT
Background: Dengue viruses are the most widespread arboviruses (transmitted mainly by Aedes aegypti 
and Ae. albopictus mosquitoes), which have shown an unexpected geographic expansion. There are four 
dengue virus serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Subsequent infections increase the risk 
of developing severe dengue fever.
Materials and methods: Samples from travellers returning from the endemic area of dengue fever were 
examined with the reverse transcription-polymerase chain reaction method. Primers amplified 743 bp 
fragment of the NS5 and 3’UTR genomic region of mosquito-borne flaviviruses of JEV group were used.
Results: The sequences from the 10 examined patients were compared to available DENV sequences in 
GenBank database and the basic local alignment search tool (BLAST) results confirmed that the infective 
virus was DENV-1 (6 patients), DENV-2 (2 patients) and DENV-3 (2 patients). 
Conclusions: For the first time in Poland, dengue virus serotypes were determined in travellers returning 
from dengue-endemic areas. 
(Int Marit Health 2015; 66, 2: 72–76)
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INTRODUCTION
Dengue fever is an acute infectious disease caused 
by DENV — a single stranded ribonucleic acid (RNA) virus 
of the family Flaviviridae, genus Flavivirus. Dengue virus 
(DENV) comprises of four genetically and antigenically dis-
tinct serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) with 
numerous virus strains found worldwide [1]. 
The natural cycle of dengue involves human-mosqui-
to-human transmission. Mosquitoes can also infect non-hu-
man primates in a sylvatic cycle [2], although symptoms 
typical for human infection are rarely seen in them [3]. 
Infection is transmitted by mosquitoes of the genus Aedes 
(Stegomyia), mainly Ae. (S.) aegypti (L) [4], less frequently 
by the tiger mosquito Ae. (S.) albopticus (Skuse) [5] and 
other species of Aedes mosquitoes, e.g. the Polynesian 
tiger mosquito Ae. (S.) polynesiensis Marks. Vertical DENV 
transmission is possible (transovarial in mosquitoes) [6, 7] 
and with breast milk in humans [8]. Infection with any of 
these viruses can be asymptomatic, it may cause a self-lim-
ited febrile illness — dengue fever (DF), or it may result in 
a life-threatening syndrome called dengue haemorrhagic fever 
(DHF) or dengue shock syndrome (DSS) [9, 10]. Current cri-
teria of the World Health Organisation (WHO) classify dengue 
according to its clinical severity: dengue without warning 
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signs, dengue with warning signs and severe dengue (den-
gue with severe plasma leakage, severe bleeding, or organ 
failure) [11]. Dengue is the most common mosquito-borne 
viral infection in the world, which is endemic in more than 
100 countries in tropical and subtropical regions [12], many 
of which are popular tourist destination. After more than 
6 decades autochthonous dengue cases have been reported 
in Europe again: in southern France [13, 14] and Croatia 
[15]. According to the WHO, global incidence of dengue has 
increased in recent decades and there are annually more 
than 50 million cases and 22,000 deaths [16, 17]. Actual 
numbers of both deaths and cases of disease due to dengue 
virus are certainly higher than those reported to the WHO 
[18]. Rapid dengue spread in the world may be associated 
with unplanned urbanisation, crowding, overpopulation, 
a weakened public-health infrastructure and international 
travel introducing new serotypes, genotypes and new strains 
to different parts of the world [19]. However, the factors 
influencing the increased frequency of dengue epidemics 
and severity are not fully understood [20]. 
Infection with one serotype of DENV can predispose 
for the development of severe dengue on reinfection with 
another serotype [21]. Dengue is rarely diagnosed in Poland; 
however, the number of Polish travellers to subtropics and 
tropics, including endemic regions where this illness occurs, 
increases every year [22].
In this study, we report some molecular data of DENV 
detected in blood and serum samples from Polish travellers 
returning from dengue endemic areas.
MATERIALS AND METHODS
A retrospective study was performed on serum and 
blood samples from patients from University Centre for 
Maritime and Tropical Medicine in Gdynia during the period 
2007–2013. Routine laboratory diagnosis of dengue fever 
was performed at the Department of Tropical Parasitology, 
Institute of Maritime and Tropical Medicine, Medical Uni-
versity of Gdansk by detection of specific immunoglobulins 
using enzyme-linked immunosorbent assay Dengue IgM 
ELISA and Dengue IgG ELISA IBL (Hamburg, Germany). In both 
tests samples were considered positive if the absorbance 
value was higher than 10% over the cut-off, and negative if 
the absorbance was lower than 10% cut-off. Samples with 
an absorbance value of 10% above or below the cut-off were 
treated as equivocal.
Whenever possible, serum samples for molecular in-
vestigation were obtained from the earliest blood draw. 
Serum and blood samples (n = 57), for which IgM detection 
proved negative, borderline or positive, were qualified for 
molecular testing. 
Viral RNA was extracted from blood and serum using 
a commercial Total RNA kit (A & A Biotechnology, Gdynia, 
Poland) according to the manufacturer’s instruction and the 
obtained templates were kept frozen in –80oC for further 
investigation. The primers specific for JEV group: forward 
WNV10090f 5’-GARTGGATGACVACRGAAGACATGCT-3’ and 
reverse WNV10807r 5’-GGGGTCTCCTCTAACCTCTAGTCCTT-3’, 
designed on the non-structural protein 5 (NS5) and 3’-un-
translated region 3 (UTR3), respectively, were applied on the 
RNA extracts [23]. Reverse transcription-polymerase chain 
reaction (RT-PCR) was performed using QIAGEN OneStep 
RT-PCR Kit (Qiagen, Germany) as described previously [23]. 
PCRs were conducted in 20 µL reaction mixture volume and 
under the conditions: 30 min at 50oC for reverse transcription, 
95oC for initial denaturation followed by 40 cycles: 40 s at 
94oC denaturation, 50 s at 57oC annealing, 1 min at 72oC 
extension and 7 min final extension at 72oC [24]. Positive 
(DENV-2 positive serum sample from previous investigation 
confirmed by sequencing) and negative (double distilled water 
— DDW instead of cDNA) controls were run with each RT-PCR 
reaction. All RT-PCR reactions were carried out in Mastercycler 
epgradient (Eppendorf) cycler. PCR products were analysed 
after electrophoresis in 1.5% agarose gel stained with ethid-
ium bromide. A ~700 bp band was considered positive. 
Sequencing of PCR-positive products was carried out with ABI 
Prism Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems), according to the manufacturer’s instructions, 
and an ABI Prism 310 Genetic Analyser (Applied Biosyste-
ms, Foster City, CA, USA) automated sequencing system. 
Sequences were edited and compared with representative 
gene sequences deposited in GenBank database using NCBI 
BLAST software (http://www.ncbi.nlm.nih.gov/BLAST) (U.S. 
National Institute of Health, Bethesda, Maryland). 
RESULTS
A retrospective study was performed on 57 blood and 
serum samples from 48 patients. Positive results were 
obtained from 10 (20.83%) patients. The majority of them 
(n = 7) travelled to Southeast Asia (Thailand, Indonesia, 
Philippines and India), 2 to South America (Brazil) and 1 to 
Africa (Chad) (Table 1). Three dengue virus serotypes were 
identified: DENV-1, DENV-2 and DENV-3. 
DENgUE SEROTyPE 1
DENV-1 was the most frequently detected serotype in 
our study. Altogether sequences of 6 isolates were identi-
fied: 3 from Southeast Asia (H26.Pl; H27.Pl, H58.Pl), 2 from 
South America (H28.Pl; H29.Pl) and 1 from Africa (H40.Pl) 
(Tables 1, 2).
The obtained sequence of isolate H26.Pl from Indonesia 
showed 100% similarity with the deposited in GenBank 
sequence KC762653.1 from Indonesian patient (Table 2).
 Of the 2 isolates from Thailand, sequence of H27.Pl was 
the most similar (99.4%) to the 2 sequences KC762628 
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Table 1. Dengue virus (DENV) serotypes imported to Gdynia, 
Poland in the years 2007–2013
DENV
serotype
No. of 
isola-
tes 
Country of origin/ 
/No. of strains
Isolate
DENV-1 6 South America 2 Brazil
Brazil
H28.Pl
H29.Pl
Africa 1 Chad H44.Pl
Asia 3 Indonesia 
Thailand
Thailand
H26.Pl
H27.Pl
H58.Pl
DENV-2 2 Asia 2 Thailand
India
H3.Pl
H7.Pl
DENV-3 2 Asia 2 Philippines
Thailand
H17.Pl
H44.Pl
and KC762653 (human hosts) from Indonesia, while se-
quence of H58.PL to 2 sequences FJ196844 (cell culture) 
and FJ176779 (human host) from southern China (99% 
homology) (Table 2).
Finally, the 2 sequences of isolates from South Ameri-
ca, H28.Pl and H29.Pl, were identical to each other and dif-
fer by 1 nucleotide (99.8% level of the sequence similarity) 
from DENV-1 virus sequences from GenBank: KC629499; 
KC629505; KC629508; KC6294510 (C – T in position 
10348), KC692501 (A – G in position 10264) (human 
hosts) from Argentina and EU482610 and FJ850102 
(T – C in position 10322) (human hosts) from Venezuela 
(Table 2).
The quality and length of the sequence from Chad (H40.
Pl) enabled dengue virus serotype 1 identification, however 
it was not possible to determine the highest identity level 
with any of homologous sequences deposited in the Gen-
Bank database.
DENgUE SEROTyPE 2
The partial sequence of DENV-2 obtained from patients 
who returned from Thailand (H3.Pl) and India (H7.Pl) showed 
99.7% homology to the sequence EU179858 from cos-
mopolitan Brunei DEN-2 virus genotype deposited in the 
GenBank database (Table 2).
DENgUE SEROTyPE 3
DENV-3 was identified in 2 patients who returned from 
Philippines (H17.Pl) and Thailand (H44.Pl). The sequence 
from Philippines showed 98.9% similarity to the deposited 
in GenBank sequence DQ675519 from a dengue fever 
patient from Taiwan (Tables 1, 2). 
The quality of the sequence from Thailand enabled se-
rotype 3 identification only, without further determination 
of homology with other sequences.
DISCUSSION
Until 2005, no epidemiological data and diagnostic 
tests were performed in Poland regarding dengue virus 
infection [22]. In the years 2006–2009, the serological 
tests performed in the University Centre for Maritime and 
Tropical Medicine demonstrated that 149 travellers (pa-
tients of the Clinic of Tropical and Parasitic Diseases of the 
Medical University of Gdansk and the Outpatient Clinic of 
Infectious, Tropical and Parasitic Diseases of the Univer-
sity Centre for Maritime and Tropical Medicine in Gdynia) 
who were subjected for routine examinations after the stay 
in the tropics might have been infected by DENV, 16 of 
the examined patients were diagnosed with dengue fever 
and 3 with dengue haemorrhagic fever [25]. In the same 
period, according to epidemiological reports by the Nation-
al Institute of Hygiene and Chief Sanitary Inspectorate, 
11 dengue cases were diagnosed in Poland [26–29]. In the 
years 2002–2011 in the Hospital Ward of Tropical Diseas-
es and Zoonoses in Warsaw, 22 patients with the clinical 
course of the disease were hospitalised [30]. This data 
prove inadequate attention paid to this disease, despite 
the increase in recreational and occupational international 
travel, which include tropical and subtropical destinations. 
Autochthonous cases reported in southern Europe [13–15] 
show that this disease reemerged in Europe and the num-
ber of imported dengue cases in Poland may rise in the 
future. Dengue viraemia is short and is usually observed 2 to 
3 days before the onset of fever, and lasts 4 to 5 days later 
[31], which explains why RNA was isolated only in 10 of 
57 serum samples included into the study. Moreover, mo-
lecular studies are not routinely performed. Thus, blood 
samples are often taken in the disease phase in which 
serum antibody detection is probable, while at the same 
time viraemia is usually not seen.  
Nucleic acid sequencing confirmed the homology of the 
three serotypes: DENV-1, DENV-2 and DENV-3. DENV-1 was 
the most frequently detected serotype within our study. This 
serotype was also seen most often in European travellers 
studied in the years 2002–2008 [20]. During the 70 years of 
studies on dengue serotypes spread and circulation, the ma-
jority of cases reported were caused by DENV-1 infection [32].
Dengue viruses can be isolated from the blood of pa-
tients during the early phase of acute dengue illness, when 
immunoglobulin M antibodies may not be detectable [1]. 
However, virus isolation requires the use of tissue culture 
assays, involving incubation periods of a week or longer. 
Molecular diagnostic systems using RT-PCR for detecting 
dengue viral RNA in human serum or plasma samples have 
been shown to be faster assays than cell culture and are 
highly effective for diagnosing dengue fever cases [33]. 
The mechanisms of dengue virus pathogenesis are little 
understood, however some studies showed that during 
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secondary dengue infections the pathophysiology of the dis-
ease changes significantly, particularly sequential infections in 
which infection with DENV-1 is followed by infection with DENV-
2 or DENV-3, or infection with DENV-3 is followed by infection 
with DENV-2 [34]. Secondary dengue infection is considered 
a risk factor for severe clinical course of the disease, which is 
explained by non-neutralising, cross-reacting antibodies from 
the first infection enhancing the infecting ability of the virus 
[35]. This phenomenon makes the information on DENV sero-
type responsible for the infection in the patient very important. 
CONCLUSIONS
Along with the increase in numbers of travellers from 
Poland visiting dengue endemic areas, molecular methods 
of DENV detection should be introduced into the routine 
dengue diagnostics performed in this group of patients.
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